J 2022

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

ŘIHÁČEK, Michal, Iveta SELINGEROVÁ, Ivo KOCÁK, Ilona KOCÁKOVÁ, Eva ŘIHÁČKOVÁ et. al.

Basic information

Original name

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

Authors

ŘIHÁČEK, Michal (203 Czech Republic, guarantor, belonging to the institution), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Ivo KOCÁK (203 Czech Republic, belonging to the institution), Ilona KOCÁKOVÁ (203 Czech Republic), Eva ŘIHÁČKOVÁ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution)

Edition

CURRENT ONCOLOGY, Basel, MDPI, 2022, 1198-0052

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.600

RIV identification code

RIV/00216224:14110/22:00125957

Organization unit

Faculty of Medicine

DOI

UT WoS

000816104700001

Keywords in English

sunitinib; mean corpuscular volume; MCV; toxicity

Tags

Tags

International impact, Reviewed
Změněno: 10/1/2023 15:02, Mgr. Tereza Miškechová

Abstract

V originále

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.

Links

MUNI/A/1427/2021, interní kód MU
Name: Personalizovaná léčba v dětské onkologii: na cestě k „liquid dynamic medicine“ a „N-of-1 clinical trials“
Investor: Masaryk University
90125, large research infrastructures
Name: BBMRI-CZ III
90128, large research infrastructures
Name: CZECRIN III